Clinical utility of novel biomarkers for cardiovascular disease risk stratification

2012 ◽  
Vol 7 (S3) ◽  
pp. 263-270 ◽  
Author(s):  
Maurizio Averna ◽  
Davide Noto
Keyword(s):  
Cardiovascular Disease ◽  
Risk Stratification ◽  
Clinical Utility ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Novel Biomarkers

scholarly journals Cardiovascular Disease Risk Prediction in Women: Is There a Role for Novel Biomarkers?

2014 ◽  
Vol 60 (1) ◽  
pp. 88-97 ◽  
Author(s):  
Nina P Paynter ◽  
Brendan M Everett ◽  
Nancy R Cook
Keyword(s):  
Cardiovascular Disease ◽  
Risk Prediction ◽  
Predictive Accuracy ◽  
Disease Risk ◽  
Troponin T ◽  
Cardiovascular Disease Risk ◽  
High Sensitivity ◽  
Preventive Therapy ◽  
Cvd Risk ◽  
Novel Biomarkers

Abstract BACKGROUND Risk prediction is an integral part of the current US guidelines for cardiovascular disease in women. Although current risk prediction algorithms exist to identify women at increased 10-year risk of cardiovascular disease (CVD), clinicians and researchers have been interested in developing novel biomarkers that might improve predictive accuracy further. These biomarkers have led to important insights into the pathophysiology of CVD, but results for their ability to improve prediction or guide preventive therapy have been mixed. The incidence of CVD is lower in women than men, and the effects of a number of traditional biomarkers on CVD risk differ in women compared to men. Both of these factors influence the ability to accurately predict CVD risk. CONTENT We review the distinctive aspects of CVD risk prediction in women, discuss the statistical challenges to improved risk prediction, and discuss a number of biomarkers in varying stages of development with a range of performance in prediction. SUMMARY A variety of biomarkers from different pathophysiologic pathways have been evaluated for improving CVD risk. While many have been incompletely studied or have not been shown to improve risk prediction in women, others, such as high-sensitivity troponin T, have shown promise in improving risk prediction. Increasing inclusion of women in CVD studies will be crucial to providing opportunities to evaluate future biomarkers.

Impact of the 2017 American Academy of Pediatrics’ Clinical Practice Guideline on the Identification and Risk Stratification of Youth at Increased Cardiovascular Disease Risk

Hypertension ◽  
2021 ◽  
Author(s):  
Tammy M. Brady ◽  
Kathleen Altemose ◽  
Elaine M. Urbina
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Clinical Practice ◽  
Risk Stratification ◽  
American Academy ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
American Academy Of Pediatrics

The updated clinical practice guideline (CPG) published by the American Academy of Pediatrics in 2017 introduced significant changes to the diagnostic and evaluative approach towards children with elevated blood pressure. The goals of this review were to summarize the current evidence regarding the impact of the new CPG on the identification and risk stratification of children at increased cardiovascular disease risk. Universally, the new CPG definitions of abnormal blood pressure led to more children classified as having a hypertensive blood pressure when compared with alternative definitions. Youth who moved to a higher blood pressure stage with the CPG typically had worse cardiometabolic profiles and more comorbidites. The association of CPG-defined hypertension and concurrent intermediate cardiovascular disease outcomes such as left ventricular hypertrophy and increased pulse wave velocity remains unclear; however, longitudinal data suggests an improved identification of those at greatest risk for adult cardiovascular disease with the CPG definitions. The majority of studies reviewed used blood pressure from one encounter, not replicate blood pressures from multiple visits, to define an abnormal or hypertensive blood pressure. Therefore, future studies investigating the prevalence of confirmed hypertension and the association between confirmed hypertension and outcomes are needed to optimally characterize the performance of the new CPG on identifying children at cardiovascular disease risk.

ST2 and galectin-3 as novel biomarkers for the prediction of future cardiovascular disease risk in preeclampsia

2021 ◽  
pp. 1-7
Author(s):  
Nil Atakul ◽  
Yıldız Atamer ◽  
Şahabettin Selek ◽  
Berna Kılıç ◽  
Fatmanur Koktasoglu
Keyword(s):  
Cardiovascular Disease ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Galectin 3 ◽  
Novel Biomarkers
Sign in / Sign up

Export Citation Format

Share Document